Bestat Supports CancerFree Biotech Investor Meeting
On January 28, 2026, Bestat Pharmaservices Corp. supported CancerFree Biotech in hosting an investor meeting aimed at fostering dialogue between the biopharmaceutical industry and the investment community. The meeting was initiated by Bestat’s CEO, Samuel Su, who invited more than ten venture capital firms to participate, reflecting strong investor interest in innovative biomedical development.
The meeting featured a keynote presentation by Dr. Long-Sheng Lu, Chief Medical Officer of CancerFree Biotech and an attending physician in the Department of Radiation Oncology at Taipei Medical University Hospital. Dr. Lu shared insights into CancerFree Biotech’s research progress and development strategy in the field of oncology, generating active engagement and positive feedback from attending investors.
Beyond providing CRO services such as biostatistics and data management, Bestat continues to support its partners through strategic collaboration and resource integration. By facilitating connections between innovative biotech companies and the investment ecosystem, Bestat helps accelerate the translation of research into meaningful medical solutions.
This collaboration reflects the United Nations Sustainable Development Goal SDG 17: Partnerships for the Goals, highlighting the importance of cross-sector collaboration in driving sustainable growth within the biopharmaceutical industry. Bestat remains committed to working with global partners to strengthen industry collaboration and advance biomedical innovation for the benefit of patients worldwide.
On January 28, 2026, Bestat Pharmaservices Corp. supported CancerFree Biotech in hosting an investor meeting aimed at fostering dialogue between the biopharmaceutical industry and the investment community. The meeting was initiated by Bestat’s CEO, Samuel Su, who invited more than ten venture capital firms to participate, reflecting strong investor interest in innovative biomedical development.
The meeting featured a keynote presentation by Dr. Long-Sheng Lu, Chief Medical Officer of CancerFree Biotech and an attending physician in the Department of Radiation Oncology at Taipei Medical University Hospital. Dr. Lu shared insights into CancerFree Biotech’s research progress and development strategy in the field of oncology, generating active engagement and positive feedback from attending investors.
Beyond providing CRO services such as biostatistics and data management, Bestat continues to support its partners through strategic collaboration and resource integration. By facilitating connections between innovative biotech companies and the investment ecosystem, Bestat helps accelerate the translation of research into meaningful medical solutions.
This collaboration reflects the United Nations Sustainable Development Goal SDG 17: Partnerships for the Goals, highlighting the importance of cross-sector collaboration in driving sustainable growth within the biopharmaceutical industry. Bestat remains committed to working with global partners to strengthen industry collaboration and advance biomedical innovation for the benefit of patients worldwide.